Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Tsaur

Showing results (181-190 of 195) with videos related to

Pageof 20
Sort By:
Biomedicines|September 28, 2023
Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma-Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic SegmentationGregor Duwe, Lukas Müller, Christian Ruckes, et al.
Cancers|April 12, 2022
Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile CancerAnita Thomas, Kimberly Sue Slade, Roman A Blaheta, et al.
Annals of Surgical Oncology|July 5, 2024
Temporal Trends in Urinary Diversion among Patients Undergoing Radical Cystectomy Between 1986 and 2022: Experience at the University Medical Center Mainz with 2224 CasesGregor Duwe, Mohamed M Kamal, Crispin Wiesmann, et al.
European Urology Focus|March 23, 2022
Predictors of Unfavorable Pathology in Patients with Incidental (pT1a-T1b) Prostate CancerIgor Tsaur, Roderick C N van den Bergh, Timo Soeterik, et al.
European Urology|April 10, 2020
External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node DissectionGiorgio Gandaglia, Alberto Martini, Guillaume Ploussard, et al.
European Urology Oncology|September 16, 2020
Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic ReviewGiancarlo Marra, Massimo Valerio, Isabel Heidegger, et al.
BJU International|May 18, 2018
How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculatorGiorgio Gandaglia, Roderick C N van den Bergh, Derya Tilki, et al.
Therapeutic Advances in Medical Oncology|March 11, 2022
Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art reviewIsabel Heidegger, Claudia Kesch, Alexander Kretschmer, et al.
Current Opinion in Urology|November 23, 2021
Features and management of men with pN1 cM0 prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based evidenceCharles Laine, Giorgio Gandaglia, Massimo Valerio, et al.
Cancers|January 11, 2022
Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future PerspectivesAlexander Kretschmer, Roderick C N van den Bergh, Alberto Martini, et al.
Pageof 20

Showing results (181-190 of 195) with videos related to

Sort By:
Pageof 20
Biomedicines|September 28, 2023
Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma-Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic SegmentationGregor Duwe, Lukas Müller, Christian Ruckes, et al.
Cancers|April 12, 2022
Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile CancerAnita Thomas, Kimberly Sue Slade, Roman A Blaheta, et al.
Annals of Surgical Oncology|July 5, 2024
Temporal Trends in Urinary Diversion among Patients Undergoing Radical Cystectomy Between 1986 and 2022: Experience at the University Medical Center Mainz with 2224 CasesGregor Duwe, Mohamed M Kamal, Crispin Wiesmann, et al.
European Urology Focus|March 23, 2022
Predictors of Unfavorable Pathology in Patients with Incidental (pT1a-T1b) Prostate CancerIgor Tsaur, Roderick C N van den Bergh, Timo Soeterik, et al.
European Urology|April 10, 2020
External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node DissectionGiorgio Gandaglia, Alberto Martini, Guillaume Ploussard, et al.
European Urology Oncology|September 16, 2020
Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic ReviewGiancarlo Marra, Massimo Valerio, Isabel Heidegger, et al.
BJU International|May 18, 2018
How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculatorGiorgio Gandaglia, Roderick C N van den Bergh, Derya Tilki, et al.
Therapeutic Advances in Medical Oncology|March 11, 2022
Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art reviewIsabel Heidegger, Claudia Kesch, Alexander Kretschmer, et al.
Current Opinion in Urology|November 23, 2021
Features and management of men with pN1 cM0 prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based evidenceCharles Laine, Giorgio Gandaglia, Massimo Valerio, et al.
Cancers|January 11, 2022
Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future PerspectivesAlexander Kretschmer, Roderick C N van den Bergh, Alberto Martini, et al.
Pageof 20